Navigation Links
NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
Date:11/20/2007

SOPHIA ANTIPOLIS, France, Nov. 20 /PRNewswire/ -- NicOx S.A. (Eurolist: COX) today announced that TOPIGEN Pharmaceuticals Inc. has dosed the first patients in a phase 2 proof of concept study for TPI 1020 in Chronic Obstructive Pulmonary Disease (COPD) - see TOPIGEN press release attached. This new study is expected to provide the first assessment of TPI 1020's potential activity in COPD. TPI 1020 is a new chemical entity and novel anti- inflammatory licensed by TOPIGEN from NicOx for COPD and other respiratory disorders.

This new clinical study follows the recent announcement of promising top- line results from a phase 2a study in asthmatic smokers, where TPI 1020 showed a good safety and tolerability profile, in addition to certain anti- inflammatory effects which could be potentially beneficial in COPD (see press release of September 11, 2007). COPD is a respiratory disease caused by chronic inflammation of the lungs and bronchi and represents the third-leading cause of death in the United States (see NOTE).

Pascal Pfister, Chief Scientific Officer at NicOx, said: "We believe TPI 1020, which has a novel mechanism of action due to NicOx technology, could have the potential to bring real benefits to people suffering from COPD, based on data that has been observed in preclinical studies and the recently reported asthmatic smoker safety study. The progression of the TPI 1020 program is a testament to TOPIGEN's expertise in the respiratory therapeutic area, as well as the broad potential of NicOx' technology, and we see this collaboration as a validation of our strategy of partnering with leading biopharmaceutical companies outside our key therapeutic domains. We look forward to the results of this phase 2 proof of concept study, which should provide an important assessment of the compound's activity."

Under the terms of the agreement signed between NicOx and TOPIGEN in October 2005, TOPIGEN acquired the development and commercialization right
'/>"/>

SOURCE NicOx
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ("Galmed"), ... and commercialization of a once-daily, oral therapy for ... today announced financial results for the 12 months ... 2014 Highlights: , Hosted a key opinion ... Rohit Loomba, MD, MHSc., who discussed the topic ...
(Date:3/31/2015)... March 31, 2015   Unique Pharmaceuticals , a ... complete and the company has initiated sterile compounding operations ... goal as a company is to meet and exceed ... . "Meeting the new regulations is validation of our ... the future of our industry, investing in its continued ...
(Date:3/31/2015)... , March 31, 2015 ... today announced a strategic partnership with Medidata ... for clinical research in life sciences. Offering therapeutic ... CRO has deployed Medidata,s electronic data capture (EDC), ... Biorasi,s Phase I through IV global clinical trial ...
Breaking Medicine Technology:Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 2Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 3Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 4Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 5Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 6Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 7Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 8Unique Pharmaceuticals Launches Sterile Operations under New Federal Guidance 2Unique Pharmaceuticals Launches Sterile Operations under New Federal Guidance 3Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 2Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 3Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 4
... Oct. 3, 2011 Varian Medical Systems (NYSE: ... senior managers to support the company,s ongoing growth and ... Vice President for the company, has been named Chief ... development, production, promotion, and sale of all Varian products ...
...   PLC Medical Systems, Inc. (OTC: PLCSF) today announced ... , October 6, 2011TIME: , 11:00 AM ... "register/ watch event now" button.This will be a live, ... the company questions in real-time both in the presentation ...
Cached Medicine Technology:Varian Medical Systems Announces New Management Positions 2Varian Medical Systems Announces New Management Positions 3Varian Medical Systems Announces New Management Positions 4PLC Medical Systems to Present Webcast Live, at RetailInvestorConferences.com on October 6th 2
(Date:3/31/2015)... Stem cells may provide Crohn’s disease ... – fistulas – according to the results of a ... of STEM CELLS Translational Medicine (SCTM). After receiving an ... are collected from fat tissue, the fistulas in 75 ... eight weeks of their last treatment and remained so ...
(Date:3/31/2015)... 31, 2015 Diane Blackburn-Zambetti is ... the Mesothelioma Applied Research Foundation (Meso Foundation). Blackburn-Zambetti ... Your Health” at the BoRit Asbestos Superfund Citizen ... This program will discuss anatomy, six types of ... diseases, symptoms, treatments, prevention and proper communication with ...
(Date:3/31/2015)... PharmMD CEO Robert Yeager ... newly created, senior executive role of Chief Technology Officer ... delivery of high quality, efficient, reliable, and secure applications, ... momentum as a market innovator for Part D Star ... “We were very strategic in our search for the ...
(Date:3/31/2015)... Mega Photo, from the makers of Slidezilla, have created ... free app brings a new found life to photos and ... masterpieces. Mega Photo provides over a 100 effects for users ... images in 3-D. , Founder Paul Falstad said that ... it has real-time view so users can try out any ...
(Date:3/31/2015)... St. Louis, MO (PRWEB) March 31, 2015 ... April 8, 2015 from 5:00 to 8:00 pm at the ... than 50 hospitals, clinics and groups with career opportunities will ... represented. Attendees will enjoy free hors d’oeuvres and raffle prize ... PracticeMatch says “Denver is an ideal location to hold ...
Breaking Medicine News(10 mins):Health News:Trial Shows Stem Cells Provide Long-Term Relief from Dangerous Crohn’s Side Effect 2Health News:Mesothelioma Foundation to speak at BoRit Asbestos Superfund Citizen Advisory Group Meeting 2Health News:PharmMD Places Victor Mattingly in C-Suite, Company Focused on Medication Therapy Management and Part D Star Ratings 2Health News:New Mega Photo App Launched and Provides the Ultimate Playground for Photos 2Health News:PracticeMatch to Host Physician Career Fair at SpringHill Suites Denver on April 8, 2015 2Health News:PracticeMatch to Host Physician Career Fair at SpringHill Suites Denver on April 8, 2015 3
... ... ... , ... , , , ...
... workshop have been released to address deep-vein thrombosis (DVT) ... estimated to affect nearly 1 million Americans each year. ... representatives from federal health agencies and patient groups, as ... communities appear in the March 9, 2010, ...
... a successful relationship partners shouldn,t go to bed angry. ... that brain activityspecifically in the region called the lateral prefrontal ... in the days following a fight with his or her ... lateral prefrontal cortex are less likely to be upset the ...
... oophorectomy) while performing a hysterectomy is common practice to ... procedure is performed in 55 percent of all US ... year. An article in the March/April issue of t ... ovaries (bilateral oophorectomy) while performing a hysterectomy is common ...
... anxiety, depression and stress lessened, researchers say , TUESDAY, March ... psychological woes in patients with lupus who have high levels ... also helps these patients improve and maintain their quality of ... included 45 patients randomly assigned to a control group or ...
... ... only seven one-hundredths of one percent of the products manufactured by the company. , ... Dinuba, CA (Vocus) March 9, 2010 ... potential salmonella exposure. To date, no salmonella-related illnesses have been reported in conjunction to ...
Cached Medicine News:Health News:South Dakota Students with Asthma Can Breathe Easier After New Law Allows Self-Administered Medications 2Health News:Critical recommendations unveiled: Deep-vein thrombosis and pulmonary embolism 2Health News:Critical recommendations unveiled: Deep-vein thrombosis and pulmonary embolism 3Health News:After a fight with a partner, brain activity predicts emotional resiliency 2Health News:New study questions benefits of elective removal of ovaries during hysterectomy 2
PremierEdge™ Stab Knives - 45°....
PremierEdge™ Stab Knives - 30°....
PremierEdge™ Stab Knives - 22.5°....
Lacrimal Intubation Set w/Retrieval Device. Size: Probes 23g x 4-1/4"....
Medicine Products: